Trial
NCT03001219
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
Anti-TNF-alpha
Why stopped
The trial was prematurely terminated due to a lack of efficacy of the investigational drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-29